Stephens Investment Management Group LLC Has $31.01 Million Stock Holdings in Schrödinger, Inc. (NASDAQ:SDGR)

Stephens Investment Management Group LLC increased its holdings in shares of Schrödinger, Inc. (NASDAQ:SDGR) by 4.4% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,607,656 shares of the company’s stock after purchasing an additional 67,786 shares during the period. Stephens Investment Management Group LLC owned approximately 2.21% of Schrödinger worth $31,012,000 at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. Sumitomo Mitsui Trust Group Inc. raised its holdings in shares of Schrödinger by 60.2% during the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 3,510,518 shares of the company’s stock valued at $67,718,000 after purchasing an additional 1,319,464 shares during the period. Massachusetts Financial Services Co. MA raised its stake in Schrödinger by 58.4% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 1,945,182 shares of the company’s stock worth $36,083,000 after buying an additional 717,059 shares during the period. Rubric Capital Management LP boosted its holdings in Schrödinger by 17.7% in the third quarter. Rubric Capital Management LP now owns 3,685,503 shares of the company’s stock worth $68,366,000 after acquiring an additional 555,503 shares in the last quarter. Barclays PLC grew its stake in Schrödinger by 421.6% in the third quarter. Barclays PLC now owns 107,554 shares of the company’s stock valued at $1,995,000 after acquiring an additional 86,933 shares during the period. Finally, Algert Global LLC increased its holdings in shares of Schrödinger by 45.3% during the third quarter. Algert Global LLC now owns 126,760 shares of the company’s stock valued at $2,351,000 after acquiring an additional 39,540 shares in the last quarter. Institutional investors and hedge funds own 79.05% of the company’s stock.

Schrödinger Trading Down 0.8 %

Shares of Schrödinger stock opened at $25.67 on Monday. The business’s fifty day simple moving average is $21.60 and its 200 day simple moving average is $20.27. Schrödinger, Inc. has a 12 month low of $16.67 and a 12 month high of $33.63. The firm has a market capitalization of $1.87 billion, a P/E ratio of -10.97 and a beta of 1.61.

Schrödinger (NASDAQ:SDGR) last released its earnings results on Tuesday, November 12th. The company reported ($0.52) EPS for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.12). The business had revenue of $35.30 million for the quarter, compared to the consensus estimate of $41.25 million. Schrödinger had a negative return on equity of 35.77% and a negative net margin of 91.84%. The company’s revenue for the quarter was down 17.1% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.86) earnings per share. Analysts predict that Schrödinger, Inc. will post -2.37 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on the company. BMO Capital Markets increased their target price on Schrödinger from $25.00 to $28.00 and gave the stock an “outperform” rating in a report on Wednesday, November 13th. KeyCorp boosted their target price on shares of Schrödinger from $25.00 to $27.00 and gave the stock an “overweight” rating in a research report on Friday, January 24th. Three research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Schrödinger presently has an average rating of “Moderate Buy” and a consensus target price of $32.11.

Schrödinger Company Profile

Schrödinger, Inc, together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries.